IGM-7354
Autoimmune & Inflammatory Diseases (via IL-6R)
Key Facts
Indication
Autoimmune & Inflammatory Diseases (via IL-6R)
Phase
Phase 1
Status
Active
Company
About IGM Biosciences
IGM Biosciences' mission is to harness the unique properties of engineered IgM antibodies to create superior therapeutics for cancer and autoimmune disorders. Its key achievement is the advancement of a bispecific IgM T-cell engager, imvotamab, into multiple Phase 2 trials for B-cell malignancies, alongside other clinical-stage oncology and immunology candidates. The company's strategy is to clinically validate its proprietary IgM platform, demonstrating differentiated efficacy and safety profiles that can support future partnerships or independent commercialization. IGM operates as an R&D-focused public entity, aiming to establish a new class of antibody medicines.
View full company profile